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Background: Improvement of the initial management of sarcomas after the dissemination of evidence-based
guidelines depends on the primary sarcoma location: a population-based study.
To improve the initial management of adult sarcomas, a regional expert team in Northern France performed two
actions: dissemination of evidence-based guidelines (EBG) for the management of soft tissue/visceral sarcoma and
yearly educational symposia. The aim of this study was to measure the impact of the dissemination of EBG on the
key-indicators of adult sarcoma management.
Methods: We conducted a before-after population-based study (before: 2005 with 63 cases, after: 2008–2009 with
86 cases) in the Lille area (Northern France urban/sub-urban area with 800,000 inhabitants). The following were the
key-indicators of adult sarcoma management: pre-therapeutic biopsy, appropriate tumour and chest imaging, expert
interdisciplinary discussion, expert interdisciplinary discussion before the first treatment and in operated cases, the
rate of R0 resection.
Results: There was no statistically significant difference in patient and tumour characteristics for the two time
periods in terms of gender, prior cancer, primary location, histological subtype, grade, size, metastasis and lymph
node involvement. There was no statistically significant improvement in primary tumour imaging (83 versus 87%), chest
imaging (67 vs 71%), pre-therapeutic biopsy (57 vs 58%). There was an improvement in expert multidisciplinary discussion
(37 vs 45%) or discussion before the first treatment (26 vs 44%) but no statistically significant. However, when soft tissue
and bone sarcomas were analysed separately, we observed statistically significant improvements in expert
multidisciplinary discussion (50 vs 74%, p = 0.02) and R0 resection rate (58 vs 91%, p = 0.002). In contrast, in cases
of visceral sarcoma, there was no improvement in expert multidisciplinary discussion (10 vs 16%, p = 0.7) or in R0
resection (88 vs 81%, p = 0.7).
Conclusions: The dissemination of EBG was associated with a limited improvement in sarcoma management
when measured in this before-after population-based study, and this improvement was dependent on the
primary location of the tumour. Efforts to implement these guidelines by all surgical teams that could treat
sarcoma, including visceral sarcoma, need to be made.
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Sarcomas account for approximately 2% of all adult can-
cers. Sarcomas are heterogeneous in terms of their histo-
logical sub-types, histological grades, locations (soft tissue,
bone and viscera), clinical behaviours and prognosis.
Nevertheless, at the early stages of tumour development,
the optimal management of these rare cancers is based on
a few key-rules: standardised radiological check-ups, biop-
sies of any deep and large soft tissue masses and bone tu-
mours and tailored treatment that is best defined after a
case by case analysis by a multidisciplinary committee, in-
cluding a surgeon, radiotherapist, medical oncologist,
pathologist and radiologist, with expertise in sarcoma
management. The primary goal of the management of
non-metastatic sarcoma is to achieve a large en-bloc re-
section. The achievement of clear margins resection (R0)
remains the key-prognostic factor for local control [1-3].
In France, recent efforts have been made to improve
the management of rare cancers, including sarcoma.
Since 1995, evidence-based guidelines for the manage-
ment of sarcoma (“Standard-Options-Recommendations”
for the management of soft tissue and visceral sarcoma)
have been widely disseminated to health professionals.
The sarcoma guidelines were updated in 2006, and a
second version of them was widely disseminated with
the help of regional cancer networks [4]. Later (2010),
the French Cancer Institute (INCa, “National du Can-
cer”) labelled some regional and inter-regional experts as
centres for organising expert inter-disciplinary commit-
tees (EIC) dedicated to sarcoma management.
Since 1999, physicians from the Centre Oscar
Lambret (comprehensive cancer centre) and from the
Lille University Hospital have organised weekly EIC
dedicated to sarcoma management. Since 2006, these
physicians have also organised yearly educational sym-
posia to support the dissemination of evidence-based clin-
ical practice guidelines and improve the quality of
sarcoma management. Furthermore, guidelines have been
posted on the Web-site of the Regional Reference Cancer
Center; the link to these web-accessible guidelines have
been copy-pasted on all multidisciplinary committee re-
ports sent to general practitioners and treating physicians.
The purpose of the current study was to measure the
impact of the dissemination of the clinical practice guide-
lines using a before-after analysis measuring some key-
indicators in a general population of the Lille area.
Methods
Study population
This before-after population-based study included all pa-
tients over 18 years of age with a diagnosis of sarcoma
in 2005 and 2008–2009. These patients were selected
from the general cancer registry of the Lille area [5]. The
Lille area is an urban and sub-urban area located innorthern France with approximately 800,000 inhabitants.
The sarcoma morphologies that were included in the
present study were as follows (coded with International
Classification of Diseases for Oncology - third edition -
ICD-O 3): 8710/3, 8711/3, 8800/3-8933/3, 8935/3-8940/
3, 8950/3-8951/3, 8963/3-8964/3, 8980/3-8991/3, 9040/
3-9044/3, 9120/3-9260/3, 9290/3, 9330/3,9342/3, 9364/3,
9365/3, 9473/3, 9480/3, 9508/3 and 9539/3-9581/3.
Data
The data were collected from medical records and in-
cluded civil status, date of diagnosis, topography and
morphology of the cancer coded by ICD-O 3, the staging
performed, the date of the EIC dedicated to the sarcoma,
the characteristics of the tumour and the treatment
(date, type and location).
We defined “expert teams” as those that were (a) trained
in interdisciplinary sarcoma management and (b) orga-
nised weekly interdisciplinary committees dedicated to
sarcoma management. Later (2010), these teams were la-
belled by the French Cancer Institute (INCa) for the man-
agement of sarcoma patients.Key performance indicators
We collected data regarding the key-indicators of the
initial examination and diagnosis of sarcoma [6] to
evaluate the compliance of expert teams to the proce-
dures described in the EBG for the initial check-up. This
included biopsy before planned curative-intent surgery,
appropriate primary tumour imaging and appropriate
chest imaging. Some key-indicators related to the man-
agement process were also collected: rate of incident
cases discussed by an EIC dedicated to sarcoma, rate of
incident cases discussed within the three months follow-
ing the diagnosis, the rate of incident cases discussed be-
fore the first treatment (pre-biopsy EIC) and the rate of
R0 resection among operated patients [7].Statistical analyses
The descriptive analysis used median or mean and ex-
treme values for continuous variables and frequency for
categorical variables. The comparisons were performed for
two periods: 2005 (before the dissemination of the clinical
practice guidelines) and 2008–2009 (after the dissemin-
ation). The Pearson’s Chi-2 test and Fischer’s exact test
were used as appropriate. We hypothesised that the man-
agement of sarcoma was significantly different depending
on the primary location of the sarcoma, soft tissue and
bone sarcoma versus visceral sarcoma. Both location cat-
egories were analysed separately. Furthermore, we have
explored the factors associated with R0 resection achieve-
ment. The level of significance was set at 0.05.
Table 1 Tumour and patient characteristics
Characteristics 2005 2008-2009 p univariate analysis
n. (%) n. (%)
Cases 63 - 86 -
Gender Men 21 33.3 30 34.9 0.844
Women 42 66.7 56 65.1
Age at diagnosis <60 years 34 54.0 46 53.5 0.954
≥60 years 29 46.0 40 46.5
Prior cancer Yes 16 25.4 17 19.8 0.414
No 47 74.6 69 80.23
Primary location Soft tissue 34 54.0 37 43.0 0.145
Bone 8 12.7 6 7.0
Gynaecological viscera 10 15.9 15 17.4
Other viscera 11 17.4 28 32.6
Histological subtypes Dermatofibrosarcoma 4 6.3 5 5.8 0.412
Kaposi sarcoma 0 0.0 4 4.7
Leiomyosarcoma 8 12.7 9 10.5
Liposarcoma 12 19.0 9 10.5
Synovial sarcoma 1 1.6 8 9.3
Other soft tissue sarcomas 27 42.9 39 45.3
Ewing sarcoma 2 3.2 1 1.2
Chondrosarcoma 4 6.3 4 4.7
Osteosarcoma 1 1.6 1 1.2
Other osseous sarcomas 1 1.6 1 1.2
Gastro-intestinal stromal Tumour 3 4.8 5 5.8
Histological grade Low grade 15 23.8 27 31.4 0.386
Intermediate 12 19.0 8 9.3
High 22 34.9 26 30.2
Not applicable 4 6.4 8 9.3
Unknown 10 15.9 17 19.8
Location Superficial 18 28.6 19 22.1 0.553
Deep 45 71.4 66 76.7
Unknown 0 0 1 1.2
Size <5 cm 19 30.2 16 18.6 0.243
> = 5 cm 30 47.6 50 58.1
Unknown 14 22.2 20 23.3
Lymph node involvement Yes 6 9.5 6 7.0 0.752
No 53 84.1 72 83.7
Unknown 4 6.4 8 9.3
Metastasis at diagnosis Yes 17 27.0 16 18.6 0.383
No 41 65.1 65 75.6
Unknown 5 7.9 5 5.8
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ware (ref: StataCorp. Stata: Statistical Software Release
11 College Station. TX. StataCorp LP).
Regulations and ethics
This registry was authorised by the National Ethical
Committee (“Commission Nationale Informatique et
Libertés”, CNIL).
Results
Patient and tumour characteristics
In the Lille area, 63 and 86 adult sarcomas were diag-
nosed in 2005 and 2008–2009, respectively. The man-
agement of sarcoma patients (surgery, radiotherapy and
chemotherapy) have been done in all hospitals covered
by the Regional Registry. However, the French National
Cancer Institute strongly supports the management of
these patients in 2 reference centers: Lille University
Hospital and Oscar Lambret Cancer Center (the 2 ex-
pert teams).” The tumour and patient characteristics are
summarised in Table 1. The median age of the patients
was 58.9 years (18.5-92.6). There were 51 men (34.2%)
and 98 women (65.8%). The main common histological
subtypes were: liposarcoma (21, 14.1%), leiomyosarcoma
(17, 11.4%), dermatofibrosarcoma (9, 6.0%), synovial sar-
coma (9, 6.0%), chondrosarcoma (8, 5.4%) and gastro-Table 2 Changes in key-indicators
Characteristics
Cases
Primary tumour imaging Yes
No and u




Case discussed in expert interdisciplinary committee Yes
No
Case discussed within the 90 days following the diagnosis (1) Yes
No
Case discussed before the first treatment (2) Yes
No





(1) – Among cases discussed in multidisciplinary meeting.
(2) – Among cases discussed in multidisciplinary meeting and treated.
(3) – Among operated patients.intestinal stromal tumour (8, 5.4%). Thirty-three
patients (22.2%) had a previous history of cancer
(mainly breast cancer, 17 cases). The mean tumour
size was 7.8 cm (1.0-25.0) in 2005 and 9.8 cm (1.4-
35.0) in 2008–2009. Seventy-four percent of the tu-
mours were profound. There was no difference
between the two periods in any of the characteristics
analysed (Table 1).Key performance indicators: before-after analysis
When comparing the data from 2005 and 2008–2009,
we observed, among cases discussed in sarcoma man-
agement, a statistically significant improvement in the
proportion of cases that were discussed within ninety
days of diagnosis (78.2 vs 97.4%, p = 0.023) and,
among cases that were operated, an improvement in
the proportion of successful R0 resections (67.3 vs
86.4%, p = 0.024). We observed also an improvement
in the rate of cases discussed by an EIC (36.5 vs
45.3%) and rate of cases discussed by an EIC before
the first treatment (26.0 vs 44.4%) but these differ-
ences were not statistically significant. There was no
difference in the rate of accurate primary tumour im-
aging, rate of accurate chest imaging, rate of cases
with biopsy (Table 2).2005 2008-2009 p univariate analysis
n. (%) n. (%)
63 - 86 -
52 82.5 75 87.2 0.427
nknown 11 17.5 11 12.8
42 66.7 61 70.9 0.578
nknown 21 33.3 25 29.1
36 57.1 50 58.1 0.903
27 42.9 36 41.9
23 36.5 39 45.3 0.279
40 63.5 47 54.7
18 78.2 38 97.4 0.023
5 21.8 1 2.6
6 26.0 16 44.4 0.155
17 74.0 20 55.6
25 45.5 32 48.5 0.740
30 54.5 34 51.5
37 67.3 57 86.4 0.024
16 29.1 8 12.1
2 3.6 1 1.5
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Improvements in the management of adult sarcoma
were observed for soft tissue and bone sarcomas
(Table 3): we observed a statistically significant increase
in the proportion of EIC discussions (50.0 vs 74.4%, p =
0.020), EIC discussions within 90 days after diagnosis
(76.2 vs 100%, p = 0.007) and R0 resections (57.9 vs
91.4%, p = 0.002). An improvement was noted in the
proportion of accurate primary tumour imaging (83.3 vs
95.4%), EIC discussion before first treatment (23.8 vs
46.7%) and first surgery by an expert team (42.1 vs
62.9%) but the improvement was not statistically signifi-
cant (p = 0.089, p = 0.097 and p = 0.076, respectively).
Among large (>3 cm) or deep soft tissue tumours, the
proportion of pre-therapeutic biopsy did not show a sta-
tistically significant increase (42.3% and 55.9% for 2005
and 2008–2009, respectively, p = 0.297). There was no
statistically significant improvement in patients with vis-
ceral sarcoma, for which only 16.3% were discussed by
an EIC.
Ro resection, discussion in multidisciplinary meeting
The achievement of R0 resection was associated with
EIC discussion in cases of bone and soft tissue sarcomaTable 3 Changes in key-indicators according to primary locat
Indicator 2005
n.
Soft tissue and bone sarcoma
Cases 42
Accurate primary tumour imaging 35
Chest CT scan 30
Biopsy 21
Expert inter-disciplinary committee discussion 21
Discussion within the 90 days following the diagnosis (1) 16
Discussion before first treatment (2) 5
First surgery by expert team (3) 16
R0 Resection (3) 22
Viscera sarcoma
Cases 21
Accurate primary tumour imaging 17
Chest CT scan 12
Biopsy 15
Expert inter-disciplinary committee discussion 2
Discussion within the 90 days following the diagnosis (1) 2
Discussion before first treatment (2) 1
First surgery by expert team (3) 9
R0 Resection (3) 15
(1) – Among cases discussed in multidisciplinary meeting.
(2) – Among cases discussed in multidisciplinary meeting and treated.
(3) – Among operated patients.(0.018) (Table 4). The achievement of R0 resection in
first surgery was associated with the surgery being per-
formed by an expert team (0.045), especially for soft tis-
sue and bone sarcomas (0.027).
Discussion
The key-findings of this study are as follows: (a) the dis-
semination of evidence-based guidelines was associated
with an improvement in sarcoma management in this
before-after population-based study and (b) the improve-
ment of sarcoma management depends on the primary lo-
cation of the tumour, with an obvious improvement in
cases of soft tissue and bone sarcomas.
Improvement of management
The role of the dissemination of evidence-based guide-
lines in the improvement of sarcoma management has
been explored in different studies, and the results of
these studies have been contradictory. In the 1990s, Ray-
Coquard et al. conducted several before-after studies in
the Rhone-Alpes region regarding breast and colo-rectal
cancer management and found that the dissemination of
guidelines was not associated with a statistically signifi-
cant improvement in the compliance to those guidelinesion
2008-2009 p univariate analysis
% n. %
- 43 -
83.3 41 95.4 0.089
71.4 33 76.7 0.576
50.0 16 60.5 0.332
50.0 32 74.4 0.020
76.2 32 100.0 0.007
23.8 14 46.7 0.097
42.1 22 62.9 0.076
57.9 32 91.4 0.002
- 43 -
81.0 34 79.1 1.000
57.1 28 65.1 0.536
71.4 24 55.8 0.229
9.5 7 16.3 0.706
100 6 85.7 1.000
50.0 2 33.3 1.000
52.9 10 32.3 0.161
88.2 25 80.7 0.694
Table 4 Factors associated with the achievement of R0 resection: univariate analysis
R0 Resection n
(%)




Discussion in expert inter-disciplinary committee
Yes 41 (82.0) 9 (18.0)
No 53 (74.7) 18 (25.3) 0.339
Discussion in expert inter-disciplinary committee: bone and soft tissue
sarcomas
Yes 39 (83.0) 8 (17.0)
No 15 (57.7) 11 (42.7) 0.018
Discussion in expert inter-disciplinary committee: visceral sarcomas
Yes 2 (66.7) 1 (33.3)
No 38 (84.4) 7 (15.6) 0.429
First surgery by expert team
Yes 42 (73.7) 15 (26.3)
No 36 (56.3) 28 (43.8) 0.045
First surgery by expert team: bone and soft tissue sarcomas
Yes 28 (73.7) 10 (26.3)
No 17 (48.6) 18 (51.4) 0.027
First surgery by expert team: visceral sarcomas
Yes 14 (73.7) 5 (26.3)
No 19 (65.5) 10 (34.5) 0.751
Percentage by row.
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conducted in the Netherlands (1998–1999 versus 2006;
79 versus 40 cases), Jansen-Landhee et al. showed a statis-
tically significant improvement in terms of compliance to
radiological check-up, pre-treatment biopsy recommenda-
tion and second opinion histological diagnosis [10]. In our
experience, we have found that the dissemination of
guidelines alone was associated with a partial improve-
ment in the compliance to guidelines. Nevertheless, we
have measured a statistically significant improvement in
the proportion of cases discussed by an EIC in the 90 days
following diagnosis (78 versus 97%, p = 0.023) and an im-
provement in the proportion of successful R0 resections
(67 versus 86%, p = 0.024).
The most interesting finding of the present study was
that the improvement of sarcoma management depends
on the primary tumour location. The improvement was
obvious in cases of soft tissue and bone sarcoma. This
can be easily explained as follows: most sarcomas are lo-
cated in the limbs and trunk, and most sarcoma patients
are referred to oncology surgical teams or orthopaedic
teams that are very involved in the organisation of the
weekly expert inter-disciplinary committee. In contrast,
patients with visceral sarcomas are referred to a variety
of surgical teams (digestive, gynaecological, head and
neck, neurological, etc.) that treat patients according to
their own guidelines, which can be different from thesarcoma guidelines. Moreover, the differential diagnosis
of visceral carcinoma and visceral sarcoma remains diffi-
cult before obtaining pathological data. There is an im-
portant difference between soft tissue masses and
visceral masses; most soft tissue masses are sarcomas
whereas most visceral masses are carcinomas. Therefore,
soft tissue masses are managed a priori as sarcoma
whilst visceral sarcomas are first treated as carcinoma,
with no systematic pre-surgical biopsy. Because sarcoma
could arise in any part of the body, efforts have to be
made to disseminate guidelines to all surgical teams and
to (re)-explain the importance of EIC before any surgical
treatment, regardless of the primary site of the tumour.
Actual management
Ray-Coquard et al. showed in a retrospective analysis of
100 sarcoma medical charts that the factors associated
with conformity to guidelines were as follows: discussion
by an expert interdisciplinary committee before surgery,
treatment by an expert team and management with an
expert network [6]. Furthermore, Sampo et al. showed
that the local control rate has been higher when pre-
treatment biopsy is performed and when patients are op-
erated on in high-volume centres [11]. We found that,
despite the dissemination of evidence-based guidelines,
the management of sarcoma remains suboptimal, espe-
cially in non-expert centres. Improvement in compliance
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fore treatment and EIC discussion, especially before
treatment. Our study shows that 77% of patients with
soft tissue and bone sarcoma underwent chest imaging,
and 56% of patients with deep or large tumours had a
biopsy; this finding is consistent with the data in the lit-
erature. For example, Heudel et al. demonstrated, in a
non-exhaustive retrospective study with more than 600
patients, that only 64% of patients underwent accurate
chest imaging and only 22% of patients with a soft tissue
mass measuring more than 3 cm underwent a pre-
treatment biopsy [12]. In our study, R0 resection was
more frequent for bone and soft tissue sarcomas when
surgery was conducted by an expert team. Several stud-
ies have stressed that there is a statistically significant
difference in terms of compliance to guidelines between
expert (or university) teams and non-expert (or non-
university) teams [7,11,13-18].Strengths and limitations
The main strengths of the present study is the
population-based design and the exhaustiveness of the
recruitment based on registry [5]. Furthermore, the col-
lection of data, based on medical files, was precise. Our
study has also some limitations. Regarding the limited
number of cases, the statistical tests have to be inter-
preted with caution: when the magnitude of difference
of proportions between the two period studied suggests
an improvement, the non-significance do not necessar-
ily mean the absence of effect but reflect a lack of
power. We have analysed the factors associated with
achievement of R0 resection. Nevertheless, regarding
the limited number of cases, we were not able to con-
duct a multivariate analysis.
Furthermore, this was a before-after retrospective
study with some inherent imprecision, we cannot dis-
tinguish the changes due to the intervention from the
simple time trend or other activities (e.g. national of
international interventions) that can influence the out-
come: a direct causality between the analysed parame-
ters and outcomes cannot be shown, especially for the
causality between the improvement of medical man-
agement and the dissemination of the guidelines. At
the end, statistically significant association does not
mean correlation; we cannot formally attribute the ob-
served changes to the diffusion of guidelines. However, our
study showed significant improvements of some key-
indicators describying the management of limb and chest
or abdominal wall sarcoma. On the contrary, there was no
improvement of visceral sarcoma, not covered by the
evidence-based guidelines. So we may assume that this is
partly caused by the dissemination of the clinical practice
guidelines.Conclusions
This study showed that the dissemination of guidelines
could be associated with improvement in sarcoma man-
agement. Efforts to implement these guidelines by all sur-
gical teams that could treat sarcoma, including visceral
sarcoma, are necessary.
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